Evidence map›Paper›PMID 42648733›Full record

ArticleHospital pediatrics2026

Sociodemographic and Clinical Factors Associated With Nirsevimab Receipt Among Children Aged Younger Than 20 Months in the New Vaccine Surveillance Network in 2023 to 2025.

Zheyi Teoh, Ayzsa Tannis, Erin Sullivan, Julie A Boom, Natasha Halasa, Marian G Michaels, Daniel C Payne, Leila C Sahni, Jennifer Schuster, Rangaraj Selvarangan and 10 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Hospital pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Zheyi TeohDepartment of Pediatrics, Seattle Children's Hospital and University of Washington, Seattle, Washington.
Ayzsa TannisCenters for Disease Control and Prevention, Atlanta, Georgia.
Erin SullivanSeattle Children's Research Institute, Seattle, Washington.
Julie A BoomTexas Children's Hospital, Houston, Texas.
Natasha HalasaDepartment of Pediatrics, Vanderbilt University Medical Center, Nashville, Tennessee.
Marian G MichaelsDepartment of Pediatrics, University of Pittsburgh School of Medicine and UPMC Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania.
Daniel C PayneDivision of Infectious Diseases, Cincinnati Children's Hospital, Cincinnati, Ohio.
Leila C SahniTexas Children's Hospital, Houston, Texas.
Jennifer SchusterChildren's Mercy, Kansas City, Missouri.
Rangaraj SelvaranganChildren's Mercy, Kansas City, Missouri.
Mary Allen StaatDivision of Infectious Diseases, Cincinnati Children's Hospital, Cincinnati, Ohio.
Laura S StewartDepartment of Pediatrics, Vanderbilt University Medical Center, Nashville, Tennessee.
Peter G SzilagyiDepartment of Pediatrics, University of Rochester School of Medicine and Dentistry, Rochester, New York.
Geoffrey A WeinbergDepartment of Pediatrics, University of Rochester School of Medicine and Dentistry, Rochester, New York.
John V WilliamsDepartment of Pediatrics, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, Wisconsin.
Fatimah S DawoodCenters for Disease Control and Prevention, Atlanta, Georgia.
Eileen J KleinDepartment of Pediatrics, Seattle Children's Hospital and University of Washington, Seattle, Washington.
Heidi MolineCenters for Disease Control and Prevention, Atlanta, Georgia.
Janet A EnglundDepartment of Pediatrics, Seattle Children's Hospital and University of Washington, Seattle, Washington.
Danielle M ZerrDepartment of Pediatrics, Seattle Children's Hospital and University of Washington, Seattle, Washington.

Funding

Intramural CDC HHS CC999999
6 · The paper itself

Abstract

objectivesWe aim to evaluate the association of sociodemographic and clinical factors with nirsevimab receipt among children with medically attended acute respiratory illness (ARI) across multiple seasons and beyond birth hospitalization. PATIENTS AND

methodsWe included nirsevimab-eligible children aged younger than 8 months and 8 to 19 months with ARI enrolled in the New Vaccine Surveillance Network during the 2023 to 2024 and 2024 to 2025 respiratory syncytial virus (RSV) seasons (October 1 to March 31). A mixed-effects logistic regression model was used to evaluate the association between sociodemographic and clinical factors with the likelihood of nirsevimab receipt among enrolled children aged younger than 8 months.

resultsOf the 2151 nirsevimab-eligible children with ARI enrolled in the 2023 to 2024 RSV season and 1819 in the 2024 to 2025 RSV season, 96% were aged younger than 8 months and in their first RSV season. Fourteen percent and 36% of eligible children aged younger than 8 months received nirsevimab in the 2023 to 2024 and 2024 to 2025 seasons, respectively. Among infants aged younger than 8 months, those born during the RSV season and those with an underlying medical condition were more likely to receive nirsevimab in both RSV seasons; infant female sex and maternal education were also associated with nirsevimab receipt during 2023 to 2024 but not 2024 to 2025.

conclusionMost nirsevimab-eligible children with medically attended ARI in this analysis did not receive nirsevimab during the first 2 seasons of nirsevimab availability. Factors such as birth before the RSV season were associated with a decreased likelihood of nirsevimab receipt, emphasizing the need for tailored interventions following birth hospitalization to increase nirsevimab uptake for this group of children.

Identifiers

PMID42648733
PMCPMC13561159

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.